Summary
This 8-K filing from Eli Lilly and Company reports the voting results from their annual shareholder meeting held on May 7, 2018. The key outcomes include the re-election of five director nominees for three-year terms, and overwhelming approval for the appointment of Ernst & Young as the principal independent auditor, as well as the advisory vote on executive compensation and the Amended and Restated 2002 Lilly Stock Plan. While these were significant approvals, investors should note that two proposals seeking to amend the Articles of Incorporation – one to eliminate the classified board structure and another to eliminate supermajority voting provisions – did not achieve the required 80% of outstanding shares for approval. Several shareholder proposals on topics such as cannabis descheduling, political contributions, animal laboratories, and drug pricing linked to executive compensation were also voted down by a significant margin.
Key Highlights
- 1Five director nominees were successfully elected to serve three-year terms ending in 2021, indicating continued shareholder confidence in the current board.
- 2Shareholders overwhelmingly approved the appointment of Ernst & Young as the principal independent auditor, a routine but important vote for corporate governance.
- 3An advisory vote on executive compensation received strong shareholder support, with a significant majority voting in favor.
- 4The Amended and Restated 2002 Lilly Stock Plan was approved by shareholders, reflecting support for the company's equity-based compensation strategies.
- 5Proposals to eliminate the classified board structure and supermajority voting provisions did not pass, requiring an 80% vote of outstanding shares, suggesting a preference for maintaining the existing governance framework among a substantial portion of shareholders.
- 6Multiple shareholder proposals, including those on cannabis, political contributions, animal laboratories, and drug pricing linked to compensation, were not approved by a significant margin.